Treatment of telangiectasia on the cheeks with a compact yellow (585 nm) semiconductor laser and a green (532 nm) KTP laser: a randomized double-blinded split-face trial.


Journal

Lasers in surgery and medicine
ISSN: 1096-9101
Titre abrégé: Lasers Surg Med
Pays: United States
ID NLM: 8007168

Informations de publication

Date de publication:
03 2019
Historique:
accepted: 07 12 2018
pubmed: 8 1 2019
medline: 28 3 2020
entrez: 8 1 2019
Statut: ppublish

Résumé

The primary objective of this study was to compare a traditional green KTP laser to a new investigational yellow laser (PhotoLase) in the treatment of facial telangiectasia in terms of the treatment outcomes. The secondary objective was to assess the functionality and reliability of the PhotoLase system from the perspective of the user. The study was a randomized split-face double-blinded study that compared the treatment efficacy of the 532-nm KTP laser and the investigational 585-nm PhotoLase laser. One or two treatments were given based on the response of the first treatment. The improvement of telangiectasia was graded according to a 7-point Telangiectasia Grading Scale (TGS) by the subjects and blinded physicians. The subjects assessed the amount of pain during the treatments using Visual Analogue Scale (VAS), and evaluated adverse effects 2-3 days after the treatment(s) using a self-assessment form. At least 50% improvement was seen in 15/18 subjects after the first PhotoLase treatment, and a similar result was observed for KTP, as assessed by the blinded physicians (P = 0.29). In the subjects' assessment, 7/18 subjects had at least 50% improvement after the first PhotoLase treatment, whereas at least 50% improvement was observed for 10/18 subjects in the KTP side, the difference being significant (P = 0.008). The amount of pain was higher with PhotoLase compared to KTP (67.7 vs. 34.6, P < 0.001). There was no difference in the frequency of erythema, crusting or purpura between the devices, but more blistering and less edema were seen after PhotoLase treatment (P < 0.05). Treatment with PhotoLase was evaluated to be 4.7-fold faster than with KTP and the PhotoLase system was more compact, narrower, lighter, and easier to carry than KTP. The investigational PhotoLase laser enables significantly faster treatments, but the process is somewhat more painful than with KTP, otherwise providing a similar clinical outcome in the treatment of facial telangiectasia. Treatment Protocol Lasers Surg. Med. 51:223-229, 2019. © Wiley Periodicals, Inc.

Identifiants

pubmed: 30614016
doi: 10.1002/lsm.23051
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-229

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Toni Karppinen (T)

Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Department of Dermatology, Tampere University Hospital, Tampere, Finland.
Epilaser Oy, Lempäälä, Finland.

Emmi Kantola (E)

Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland.

Ari Karppinen (A)

Epilaser Oy, Lempäälä, Finland.

Antti Rantamäki (A)

Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland.

Hannu Kautiainen (H)

Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland.
Department of General Practice, University of Helsinki, Helsinki, Finland.
Unit of Primary Health Care, Kuopio University Hospital, Kuopio, Finland.

Serge Mordon (S)

The French National Institute of Health and Medical Research (INSERM), INSERM U1189-ONCO-THAI, avenue Oscar Lambert 1, 59037, Lille Cedex, France.

Mircea Guina (M)

Optoelectronics Research Centre, Tampere University of Technology (TUT), Korkeakoulunkatu 3, 33720, Tampere, Finland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH